IL311227A - Therapeutic bacteriophage compositions - Google Patents
Therapeutic bacteriophage compositionsInfo
- Publication number
- IL311227A IL311227A IL311227A IL31122724A IL311227A IL 311227 A IL311227 A IL 311227A IL 311227 A IL311227 A IL 311227A IL 31122724 A IL31122724 A IL 31122724A IL 311227 A IL311227 A IL 311227A
- Authority
- IL
- Israel
- Prior art keywords
- equipment
- bacteriophage composition
- bacteriophage compositions
- mutant
- combinations
- Prior art date
Links
- 241001515965 unidentified phage Species 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title claims 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 241000894006 Bacteria Species 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Claims (6)
1.claimsversion CLAIM S 1. A method of killing bacteria on a surface, said method comprising applying a bacteriophage composition comprising one or more bacteriophages selected from Sa87, J-Sa36, Sa83, and mutants thereof to the surface, wherein the surface is equipment, bedding, furniture, walls, floors, or combinations thereof.
2. A method according to claim 1, wherein the equipment is medical equipment.
3. A method according to claim 1 or 2, wherein the mutant has at least 90% sequence identity across its entire genome when compared to Sa87, J-Sa36, or Sa83.
4. A method according to claim 1 or 2, wherein the mutant has at least 95% sequence identity across its entire genome when compared to Sa87, J-Sa36, or Sa83.
5. A method according to claim 1 or 2, the bacteriophage composition comprising at least two bacteriophages selected from Sa87, J-Sa36, or Sa83.
6. A method according to claim 1 or 2, the bacteriophage composition consisting essentially of Sa87, J-Sa36, or Sa83 and a pharmaceutically acceptable carrier, diluent, excipient or combinations thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2017/050376 WO2018146437A1 (en) | 2017-02-13 | 2017-02-13 | Therapeutic bacteriophage compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311227A true IL311227A (en) | 2024-05-01 |
Family
ID=58358746
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL268514A IL268514B1 (en) | 2017-02-13 | 2017-02-13 | Therapeutic bacteriophage compositions |
| IL311227A IL311227A (en) | 2017-02-13 | 2017-02-13 | Therapeutic bacteriophage compositions |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL268514A IL268514B1 (en) | 2017-02-13 | 2017-02-13 | Therapeutic bacteriophage compositions |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20190359947A1 (en) |
| EP (1) | EP3579853A1 (en) |
| JP (2) | JP7370867B2 (en) |
| CN (1) | CN110719784A (en) |
| AU (1) | AU2017398266A1 (en) |
| CA (1) | CA3053450A1 (en) |
| IL (2) | IL268514B1 (en) |
| WO (1) | WO2018146437A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10517908B2 (en) * | 2015-08-13 | 2019-12-31 | Armata Pharmaceuticals, Inc. | Therapeutic bacteriophage compositions |
| US11654166B2 (en) | 2018-01-02 | 2023-05-23 | Armata Pharmaceuticals, Inc. | Therapeutic bacteriophage compositions for treating Staphylococcus infection |
| WO2020254967A1 (en) * | 2019-06-17 | 2020-12-24 | Phagelux Canada Inc. | Bacterial control through dispersion of bacteriophage powders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005009451A1 (en) | 2003-07-23 | 2005-02-03 | Biocontrol Limited | Bacteriophage-containing therapeutic agents |
| GB0704553D0 (en) | 2007-03-09 | 2007-04-18 | Harper David R | Beneficial effects of bacteriophage treatments |
| WO2009044163A2 (en) | 2007-10-04 | 2009-04-09 | Novolytics Limited | Anti-bacteria compositions |
| GB201119167D0 (en) | 2011-11-07 | 2011-12-21 | Novolytics Ltd | Novel bachteriophages |
| SI2874635T1 (en) | 2012-05-04 | 2020-07-31 | Armata Pharmaceuticals, Inc. | Therapeutic bacteriophage compositions |
-
2017
- 2017-02-13 IL IL268514A patent/IL268514B1/en unknown
- 2017-02-13 CN CN201780086424.6A patent/CN110719784A/en active Pending
- 2017-02-13 AU AU2017398266A patent/AU2017398266A1/en active Pending
- 2017-02-13 JP JP2019565067A patent/JP7370867B2/en active Active
- 2017-02-13 WO PCT/GB2017/050376 patent/WO2018146437A1/en unknown
- 2017-02-13 IL IL311227A patent/IL311227A/en unknown
- 2017-02-13 CA CA3053450A patent/CA3053450A1/en active Pending
- 2017-02-13 EP EP17711727.2A patent/EP3579853A1/en active Pending
- 2017-02-13 US US16/485,408 patent/US20190359947A1/en not_active Abandoned
-
2022
- 2022-01-27 JP JP2022010645A patent/JP7449967B2/en active Active
- 2022-10-25 US US18/049,382 patent/US20230272352A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7449967B2 (en) | 2024-03-14 |
| CA3053450A1 (en) | 2018-08-16 |
| US20230272352A1 (en) | 2023-08-31 |
| IL268514A (en) | 2019-09-26 |
| WO2018146437A1 (en) | 2018-08-16 |
| JP2020520980A (en) | 2020-07-16 |
| AU2017398266A1 (en) | 2019-09-12 |
| JP7370867B2 (en) | 2023-10-30 |
| JP2022062116A (en) | 2022-04-19 |
| EP3579853A1 (en) | 2019-12-18 |
| US20190359947A1 (en) | 2019-11-28 |
| IL268514B1 (en) | 2024-07-01 |
| CN110719784A (en) | 2020-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019013954A (en) | Covalent inhibitors of kras. | |
| WO2017152137A9 (en) | Microbial consortium and uses thereof | |
| WO2016154016A3 (en) | Tat-induced crispr/endonuclease-based gene editing | |
| EP3934652A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
| WO2018013583A3 (en) | Medicinal vaginal lactobacillus cocktail | |
| WO2020140054A8 (en) | Cyclin-dependent kinase inhibitors | |
| WO2017191130A3 (en) | Arginase inhibitors and their therapeutic applications | |
| EP3536168A3 (en) | Probiotic formulations and methods for use | |
| WO2021016112A3 (en) | Non-sedating dexmedetomidine treatment regimens | |
| IL311227A (en) | Therapeutic bacteriophage compositions | |
| EP4375382A3 (en) | Bacterial strains having fungicidal activity, compositions comprising same and use thereof | |
| WO2016142708A3 (en) | Pharmaceutical composition | |
| EP4252755A3 (en) | Therapeutic compounds | |
| PH12021551268A1 (en) | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | |
| EP3927710A4 (en) | Compositions and methods for treating or preventing alzheimer's disease | |
| MY197917A (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
| MX2021003606A (en) | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases. | |
| WO2021004958A3 (en) | Compositions comprising bacterial strains | |
| WO2018109042A3 (en) | Antimicrobial peptides | |
| MX2021005421A (en) | C11-cyclic substituted 13-membered macrolides and uses thereof. | |
| WO2015130547A8 (en) | Bis-cyclic guanidine compound compositions, methods of use and treatment thereof | |
| MX2021005423A (en) | C10-alkylene substituted 13-membered macrolides and uses thereof. | |
| WO2022106897A3 (en) | Methods and composition for kras modifications | |
| EP4114393A4 (en) | Methods for the treatment and prevention of lung infections by administration of tafenoquine | |
| WO2018151562A3 (en) | Novel benzimidazole derivative having jnk inhibitory activity and use thereof |